The New Zealand Black Mouse as a Model for the Development and Progression of Chronic Lymphocytic Leukemia

被引:12
|
作者
Salerno, Erica [1 ]
Yuan, Yao [1 ]
Scaglione, Brian J. [1 ,2 ]
Marti, Gerald [3 ]
Jankovic, Alexander [3 ]
Mazzella, Fermina [1 ]
Laurindo, Maria Fernanda [1 ]
Despres, Daryl [4 ]
Baskar, Sivasubramanian [5 ]
Rader, Christoph [5 ]
Raveche, Elizabeth [1 ]
机构
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Lab Med & Pathol, Newark, NJ 07103 USA
[2] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA
[3] US FDA, Ctr Biol Evaluat & Res, NIH, Bethesda, MD 20892 USA
[4] NINDS, Mouse Imaging Facil, NIH, Bethesda, MD 20892 USA
[5] NCI, NIH, Bethesda, MD 20892 USA
关键词
chronic lymphocytic leukemia; monoclonal B cell lymphocytosis; miR-16; murine model of CLL; New Zealand Black; side population; B-CELL LYMPHOCYTOSIS; SIDE POPULATION; STEM-CELLS; CLL; GENES; CANCER; 13Q14; RNA; IDENTIFICATION; MICRORNA-16;
D O I
10.1002/cyto.b.20544
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Similar to a subset of human patients who progress from monoclonal B lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL), New Zealand Black (NZB) mice have an age-associated progression to CLL. The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16. Methods: Spleens of aging NZB were analyzed for the presence of B-1 cells via flow cytometry and for the presence of a side population (SP) via the ability of cells to exclude Hoechst 33342 dye. The SP was assayed for the presence of hyperdiploid B-1 clones and for the ability to differentiate into B-1 cells in vitro and transfer disease in vivo. In addition, enhanced apoptosis of chemoresistant NZB B-1 cells was examined by restoring miR-16 levels in nutlin-treated cells. Results: Aging NZB mice develop a B-1 expansion and clonal development that evolves from MBL into CLL. An expansion in SP is also seen. Although the SP did contain increased cells with stem cell markers, they lacked malignant B-1 cells and did not transfer disease in vivo. Similar to B-1 cells, splenic NZB SP also has decreased miR-15a/16 when compared with C57BI/6. Exogenous addition of miR15a/16 to NZB B-1 cells resulted in increased sensitivity to nutlin. Conclusion: NZB serve as an excellent model for studying the development and progression of age-associated CLL. NZB SP cells do not seem to contain cancer stem cells, but rather the B-1 stem cell. NZB B-1 chemoresistance may be related to reduced miR-15a/16 expression. (C) 2010 International Clinical Cytometry Society
引用
收藏
页码:S98 / S109
页数:12
相关论文
共 50 条
  • [41] Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia
    Alshemmari, Salem Salem
    Almazyad, Mazyad Jamal
    Kunhikrishnan, Anita
    Al-Humood, Salah
    BLOOD, 2022, 140 : 12380 - 12381
  • [42] Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience
    Daniel Eek
    Matthew Blowfield
    Calvin Krogh
    Helena Chung
    Toby A. Eyre
    The Patient - Patient-Centered Outcomes Research, 2021, 14 : 75 - 87
  • [43] Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia
    Walsby, Elisabeth
    Buggins, Andrea
    Devereux, Stephen
    Jones, Ceri
    Pratt, Guy
    Brennan, Paul
    Fegan, Chris
    Pepper, Chris
    BLOOD, 2014, 123 (23) : 3607 - 3617
  • [44] Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience
    Eek, Daniel
    Blowfield, Matthew
    Krogh, Calvin
    Chung, Helena
    Eyre, Toby A.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (01): : 75 - 87
  • [45] Proteomics-Based Regression Model for Assessing the Development of Chronic Lymphocytic Leukemia
    Bakhtina, Varvara I.
    Veprintsev, Dmitry V.
    Zamay, Tatiana N.
    Demko, Irina V.
    Mironov, Gleb G.
    Berezovski, Maxim V.
    Petrova, Marina M.
    Kichkailo, Anna S.
    Glazyrin, Yury E.
    PROTEOMES, 2021, 9 (01) : 1 - 8
  • [46] STRATIFICATION MODEL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Zagoskina, T.
    Zotina, E.
    Shardakov, V.
    HAEMATOLOGICA, 2014, 99 : 588 - 589
  • [47] Chronic lymphocytic leukemia: a model disease for hematology
    Sigaux, Francois
    HEMATOLOGIE, 2006, 12 (05): : 293 - 293
  • [48] A mathematical model for chemoimmunotherapy of chronic lymphocytic leukemia
    Rodrigues, D. S.
    Mancera, P. F. A.
    Carvalho, T.
    Goncalves, L. F.
    APPLIED MATHEMATICS AND COMPUTATION, 2019, 349 : 118 - 133
  • [49] Conceptual model of chronic lymphocytic leukemia.
    Chung, Helena
    Blowfield, Matthew
    Krogh, Calvin
    Eek, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia
    Visone, Rosa
    Veronese, Angelo
    Balatti, Veronica
    Croce, Carlo M.
    ONCOTARGET, 2012, 3 (02) : 195 - 202